Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
TYRA-430 · 1 trial · 14 indications
MTD determination: dose limiting toxicity (DLT) rate in the first 28-day cycle
Number of participants with TEAEs as assessed by CTCAE, v5.0
To determine recommended Phase 2 dose(s) of TYRA-430
| Arm | Type | Description |
|---|---|---|
| Part A - Dose Escalation | EXPERIMENTAL | Dose escalation of TYRA-430 as monotherapy at various dose levels. |
| Part B - Cohort 1 Dose Expansion | EXPERIMENTAL | Dose expansion group for TYRA-430 monotherapy in advanced HCC at a dose(s) determined in Part A. |
| Part B - Cohort 2 Dose Expansion | EXPERIMENTAL | Dose expansion group for TYRA-430 monotherapy in advanced solid tumors at a dose(s) determined in Part A. |
| Name | Type | Description |
|---|---|---|
| TYRA-430 | DRUG | Oral TYRA-430 given daily. |
Key Inclusion Criteria: All Patients: * Age ≥ 18 years * Eastern Cooperative Oncology Group (ECOG) performance status of ≤1. * Adequate end organ function. * Ability to swallow oral formulations. * Ability to understand and willingness to sign the ICF. Part A: * Histologically confirmed locally ...
TYRA-430 is an investigational small molecule being developed for metastatic hepatocellular carcinoma and other advanced solid tumors with activating FGF/FGFR pathway aberrations. It is currently in Phase 1 clinical development and has not been approved by the FDA.
TYRA-430 targets FGFR4, a member of the fibroblast growth factor receptor family. By inhibiting FGFR4, the drug aims to interfere with signaling pathways that can drive tumor growth in cancers with FGF/FGFR pathway aberrations.
TYRA-430 is being developed by Tyra Biosciences, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol TYRA. The company is conducting clinical trials to evaluate the drug's safety and preliminary anti-tumor activity.
TYRA-430 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to assess safety and preliminary efficacy.
TYRA-430 is being studied in a Phase 1 clinical trial with the identifier NCT06915753. The trial is evaluating the safety and preliminary anti-tumor activity of TYRA-430 in advanced hepatocellular carcinoma and other solid tumors with activating FGF/FGFR pathway aberrations. The study is currently recruiting participants.